ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0457 • ACR Convergence 2023

    Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival

    Deanna Jannat-Khah1, Jeffrey R Curtis2, Fenglong Xie3, Ashish Saxena4 and Anne Bass5, 1Hospital For Special Surgery, New York, NY, 2Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
  • Abstract Number: 0736 • ACR Convergence 2023

    Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics

    Juan Vargas1, Ian Mantel2, Nirmal Banda1, Anna Helena Jonsson3, Kevin Wei4, Deepak Rao3, Susan Goodman5, Kevin Deane1, The Accelerating Medicines Partnership SLE/RA1, Jennifer Anolik6, Michael Brenner4, Soumya Raychaudhuri3, Jennifer Seifert7, Michael Holer1, Laura Donlin5 and Fan Zhang8, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2Weill Cornell Medicine, New York, NY, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Hospital for Special Surgery, New York, NY, 6University of Rochester Medical Center, Rochester, NY, 7the Accelerating Medicines Partnership (AMP) RA/SLE Network, Boston, MA, 8University of Colorado, Aurora, CO

    Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in autoimmune disease pathogenesis. In patients with rheumatoid arthritis…
  • Abstract Number: 0802 • ACR Convergence 2023

    Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

    Samuel Kemble1, Christopher Mahony2, Charlotte Smith2, Joel Rurik3, Haig Aghajanian3, Jonathan Epstein3, Mark Coles4 and Adam Croft2, 1University Birmingham, Rugeley, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
  • Abstract Number: 0968 • ACR Convergence 2023

    Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

    Yumeko Kawano1, Dana Weisenfeld1, Qing Liu1, Mary Jeffway1, Gregory McDermott1, Kumar Dahal1, Jennifer Stuart1, Jacob Joseph2, Tianrun Cai1, Brittany Weber1, Tianxi Cai3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Veteran's Affairs Boston Healthcare System, Boston, MA, 3Harvard T.H. Chan School of Public Health, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease including heart failure (HF). HF is a heterogeneous condition that is…
  • Abstract Number: 0997 • ACR Convergence 2023

    Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus

    W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI

    Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
  • Abstract Number: 1081 • ACR Convergence 2023

    Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial

    Marthe Brun1, Kristin Hammersbøen Bjørlykke2, Johanna E. Gehin3, David John Warren3, Rolf A. Klaasen3, Joseph Sexton1, Øystein Sandanger4, Tore Kvien1, Cato Mørk5, Jørgen Jahnsen2, Nils Bolstad3, Kristin Kaasen Jørgensen2, Espen Haavardsholm1, Guro Goll1 and Silje Watterdal Syversen1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 3Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, 4Section of Dermatology, Oslo University Hospital, Oslo, Norway, 5Akershus Dermatology Center, Lørenskog, Norway

    Background/Purpose: Formation of anti-drug antibodies (ADAb) to biological drugs is a clinical problem. Proactive therapeutic drug monitoring (TDM) allows for timely detection of ADAb and…
  • Abstract Number: 1274 • ACR Convergence 2023

    Rheumatoid Arthritis Patients, Achieving Low Disease Activity State or Remission, Still Demonstrate Significant Hand Disability, as Assessed by Functional Dexterity Test: A Disconnection Between CDAI and Functional Hand Assessment

    Aniela Shouval1, Amihai Levkovitch2, Itzhak Rosner3, shiri keret4, Irina Rokhyan2, Boris Tchalabian2, Esther Hof5 and Gleb Slobodin6, 1Bnai Zion Medical Center, Haifa, Israel, 2Department of Rehabilitation, Bnai Zion Medical Center, Haifa, Israel, 3Bnai Zion Medical Center/Technion, Haifa, Israel, 4Bnai Zion, Atlit, Israel, 5Occupational Therapy Unit, Bnai zion Medical Center, Haifa, Israel, 6Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel

    Background/Purpose: Direct functionality of the hand is not commonly assessed in daily practice or clinical trials in patients with rheumatoid arthritis (RA). Functional dexterity test…
  • Abstract Number: 1290 • ACR Convergence 2023

    Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis

    Katie McMenamin1, Kristin Wipfler2, Austin Wheeler3, Grant Cannon4, K Wysham5, Brian Sauer6, Bryant England3, Kaleb Michaud3, Ted R Mikuls7 and Joshua Baker8, 1Boston University, Boston, MA, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5VA Puget Sound/University of Washington, Seattle, WA, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
  • Abstract Number: 1307 • ACR Convergence 2023

    Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER

    Clementina López Medina1, Jerusalem Calvo2, Lucia Otero-Valera3, Alejandro Escudero Contreras2, Rafaela Ortega Castro4, Lourdes Ladehesa Pineda5, Cristina Campos6, Pilar Bernabeu-Gonzálvez7, Cristina Bohorquez8, Alicia Garcia Dorta9, Dolores Ruiz-Montesinos10, Manuel Enrique Pombo Suarez11, Inmaculada Ros12, Fernando Alonso3 and Isabel Castrejon13, 1Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, 2Reina Sofia University Hospital, Córdoba, Spain, 3Spanish Society of Rheumatology, Madrid, Spain, 4Hospital Reina Sofía, Cordoba, Spain, 5Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, 6Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, 7General University Hospital Dr. Balmis, Alicante, Spain, 8Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 9Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 10Hospital Universitario Virgen Macarena, Sevilla, Spain, 11Hospital Cl­ínico Universitario, Santiago de Compostela, Spain, 12Rheumatology Department HUSLL, Palma de Mallorca, Spain, 13Hospital Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities, compared to the general population. The presence of such comorbidities has been directly…
  • Abstract Number: 1324 • ACR Convergence 2023

    Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

    Roxanne Cooksey1 and Ernest Choy2, 1Cardiff University, Cardiff, United Kingdom, 2Section of Rheumatology, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
  • Abstract Number: 1340 • ACR Convergence 2023

    Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data

    Stephanie Song1, Michael George2, Ted R Mikuls3, Bryant England4, Brian Sauer5, Grant Cannon6 and Joshua Baker2, 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
  • Abstract Number: 1629 • ACR Convergence 2023

    Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative

    Kaleb Michaud1, Sofia Pedro2, Shreena Kamlesh Gandhi3 and Frederick Wolfe2, 1University of Nebraska Medical Center, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Kansas University School of Medicine, Wichita, KS

    Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
  • Abstract Number: 1723 • ACR Convergence 2023

    3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity

    Brendan Allen1, Sabrina Fechtner2, Meagan Chriswell3, Widian Jubair1, M. Aaron Vrolijk1, V. Michael Holers4 and kristine Kuhn1, 1University of Colorado School of Medicine, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of Colorado Anschutz SOM, Denver, CO, 4University of Colorado, Denver, CO

    Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
  • Abstract Number: 1741 • ACR Convergence 2023

    The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis

    Sara Turcinov1, Charlotte de Vries2, Ravi Kumar Sharma2, Christina Gerstner2, Bruno Raposo2, Anatoly Dubnovitsky2, William Kwok3, Karine Chemin2, Vivianne Malmström4 and Aase Hensvold5, 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden, 5Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden

    Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
  • Abstract Number: 1757 • ACR Convergence 2023

    Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity

    Michał Jakubaszek, Maria Maślińska and Brygida Kwiatkowska, National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland

    Background/Purpose: Usefulness of quantitative assessment of synovial vascularity in ultrasound (US) imaging in patients with active RA and PsA (peripheral arthritis). Additionally the assessment of…
  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology